Analysts seem to think that the droloxifene news will not have serious negative consequences, and that the pipeline is still strong. From Yahoo news --
``The droloxifene news is a disappointment and creates a question about the drug's potential for the other two indications Pfizer is still pursuing,'' said A.G. Edwards drug analyst Kenneth Nover.
Nevertheless, Nover said it was easily offset by Pfizer's rich pipeline of other drugs, including Viagra (sildenafil) for erectile dysfunction, dofetilide for heart arrhythmia and Zeldox (ziprasidone) for schizophrenia.
Hambrecht & Quist analyst Alex Zisson said droloxifene might have achieved annual sales of $100 million for treating breast cancer. By contrast, he said Viagra could eventually become a multibillion-dollar drug and dofetilide could achieve annual sales of $200 million to $500 million.